Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several stocks...
A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week.
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development
December S&P 500 futures (ESZ22) are trending up +0.26% this morning after three major US benchmark indices closed lower on Friday, notching their biggest weekly drop in more than a month, as hotter-than-anticipated...
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.